Enclomiphene
versus TRT.
TRT replaces testosterone. Enclomiphene aims to stimulate your own production. The right question is not which raises a number—it is which approach fits the diagnosis, goals and evidence.
Replacement versus
stimulation.
TRT supplies testosterone; enclomiphene aims to stimulate your own production. Both can raise blood testosterone in selected men, but they act differently, have different evidence and regulatory status, and are not interchangeable choices.[8][11]
| Question | TRT | Enclomiphene |
|---|---|---|
| How does it work? | Adds testosterone from outside the body. | Changes estrogen feedback to increase hormone signals to the testes. |
| What happens to LH and FSH? | Typically suppresses these signals. | Raised these signals in trials of selected men with secondary hypogonadism. |
| What about sperm? | Can suppress production, sometimes severely. | Maintained sperm concentration in short trials; that does not guarantee pregnancy. |
| U.S. approval? | FDA-approved testosterone medicines exist; approval is product- and indication-specific. | No FDA-approved enclomiphene medicine. Compounding is a separate framework. |
This guide compares approaches neutrally. It does not confirm that Bramwell prescribes or supplies enclomiphene.[4][6][8]
A low number
is not the whole story.
Enclomiphene is a selective estrogen receptor modulator (SERM). By blocking part of estrogen’s feedback signal, it can increase pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH prompts the testes to make testosterone. This requires a hormone-signaling system and testes capable of responding.[8]
Primary hypogonadism means the main problem is in the testes. Secondary hypogonadism means the brain or pituitary signaling is inadequate. LH and FSH help distinguish these patterns. Increasing the signal is not a reliable solution when the testes cannot respond; nor does every secondary cause qualify for enclomiphene.[8][11]
The trials largely studied selected men with secondary hypogonadism, including overweight men with low testosterone and low or normal LH. Those results should not be assumed to apply to primary testicular failure, pituitary disease or every man who feels tired.[6][8]
Symptoms alone do not establish testosterone deficiency. A physician evaluates the symptoms, consistent testosterone results, possible causes and whether treating an underlying problem is appropriate. Bring outside results for review; new testing depends on what information the physician needs. Our lab-testing guide explains that process.[11]
Hormone results
aren’t the same as relief.
Two randomized phase III studies compared enclomiphene with testosterone gel and placebo in overweight men aged 18–60 with secondary hypogonadism. At 16 weeks, active treatments raised total testosterone. LH and FSH rose with enclomiphene and fell with testosterone gel; sperm concentration was maintained with enclomiphene but declined with the gel.[6]
Those findings support a difference in hormone signaling and sperm effects in that population. They do not prove that enclomiphene is better for energy, mood, sexual symptoms, long-term health or achieving pregnancy. The studies were short and the principal outcomes were hormone levels and semen measurements.
A 2025 review of randomized studies of clomiphene or enclomiphene found higher testosterone than placebo and better sperm measures than testosterone gel. Because it pooled evidence about both drugs, it should not be read as proof that they are interchangeable or that every finding applies to enclomiphene alone. The review also remained underpowered for safety outcomes.[13]
FDA’s 2022 assessment specifically noted that the enclomiphene trials did not establish clinically meaningful symptom improvement, and that better semen parameters do not ensure fertility. It also identified safety concerns and gaps in long-term data. A higher testosterone result alone is not enough to declare a treatment successful.[4][5]
TRT has evidence and clinical guidance for treating appropriately diagnosed hypogonadism, but individual symptom response and risks still need monitoring. It is not a general remedy for fatigue or aging.[11]
Compounded does
not mean approved.
Enclomiphene is not an FDA-approved medication. FDA’s official assessment describes the unsuccessful approval application and the lack of an approved enclomiphene drug. Do not confuse a prescription, a pharmacy license or a compounded product with FDA drug approval.[4][5][12]
On FDA’s nominated-substances list, updated May 14, 2026, enclomiphene citrate remains in 503A Category 1: bulk drug substances under evaluation. FDA’s current guidance describes conditional interim enforcement discretion for Category 1 substances. This is not inclusion on the final 503A bulks list, an approval of the medicine, or blanket permission for any seller or formulation.[1][2]
The FDA advisory committee voted against recommending its inclusion on the final bulks list in 2022. That advisory vote and the current Category 1 listing are different facts; the vote should not be presented as either approval or a completed nationwide compounding ban.[3]
Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing. Whether a particular preparation may be compounded and dispensed depends on applicable federal and state requirements and the circumstances. The prescriber and pharmacy must verify current status rather than relying on an article.[2][12]
Enclomiphene is not the same as clomiphene. Clomiphene is a mixture containing enclomiphene and zuclomiphene; its approved-drug status does not transfer to a stand-alone enclomiphene preparation. Evidence about one should not automatically be attributed to the other.[4]
Ask about goals.
Not just a target level.
“Stimulates your own testosterone” does not mean natural, risk-free or always safer. FDA’s assessment discussed headache and hot flushes, visual complaints, and concerns about cardiac and blood-clot events; long-term safety evidence was limited. This does not establish that enclomiphene causes every reported event, but it rules out a simple “safer than TRT” promise.[4][5]
If fertility matters, make that explicit before therapy. Sperm preservation in a trial does not guarantee conception, and neither adding another hormone to TRT nor following an online recovery protocol guarantees fertility. A reproductive urologist may be appropriate.
- Is low testosterone confirmed, and what is causing it?
- Do my LH and FSH results suggest my testes could respond to stimulation?
- How do current or future plans for children change the recommendation?
- What symptom benefit is realistically supported, and how would we measure it?
- What is the exact medication’s approval or compounding status, and what safety monitoring would I need?
You cannot safely select therapy from a comparison table or one lab number. Discuss the diagnosis, fertility goals, evidence and risks with your treating physician. Return to the TRT Learning Hub for broader treatment context.
Research behind
this guide.
Clinical guidance informs care; it does not replace your treating physician’s individualized evaluation and judgment. This guide is education, not a personal treatment plan.
- Wiehle et al. (2013): Testosterone restoration using enclomiphene citrate. Full-text randomized, six-week pharmacodynamic study; selected secondary-hypogonadism population.
- Kim, McCullough & Kaminetsky (2016): Enclomiphene versus topical testosterone. Phase III study abstract; 16-week hormone and sperm outcomes.
- Endocrine Society: Testosterone therapy guideline resources (2018). Diagnosis, cause differentiation and treatment guidance.
- FDA: June 8, 2022 Pharmacy Compounding Advisory Committee transcript. Approval history, safety concerns and limitations of clinical endpoints.
- FDA: June 8, 2022 presentations. Official clinical-effectiveness and safety assessment.
- FDA: Nominated bulk substances under Section 503A. Current retrieved list updated May 14, 2026; Category 1 includes enclomiphene citrate.
- FDA: Bulk substances used in compounding under Section 503A. Interim policy and conditions; page current as of May 14, 2026.
- FDA: June 8, 2022 advisory committee meeting summary. Advisory vote on enclomiphene.
- FDA: Understanding the risks of compounded drugs. Compounded-product approval distinction; page current as of June 22, 2026.
- Clomiphene or enclomiphene for male hypogonadism: systematic review of randomized trials (2025). Pooled drug-class evidence; not proof of interchangeability, with limited safety power.
Understand the cause.
Discuss your options.
A free physician consultation can help clarify evaluation and next steps—not guarantee a particular prescription.
Treatment is prescribed only if medically appropriate following physician consultation.